What Protogenix, Inc does

Protogenix, Inc. is a privately held, pre-revenue biotechnology company developing a recombinant protein production platform intended to replace mammalian-based production systems. The company was founded in 2021 as a Delaware corporation and is headquartered in Ithaca, New York, operating with a small team of 1-10 employees. Its product is not yet commercialized; the corporate website (proto-genix.com) currently displays a 'Coming Soon' placeholder alongside the tagline 'The Future of Recombinant Protein Production,' and no named products, patents, or specific technical disclosures have been made public.

The company's core offering centers on a proprietary recombinant protein production technology. No specific upstream process, host system, or platform architecture has been publicly disclosed, and there are no documented patents, trademarks, certifications, or third-party validations in the input. Distribution is planned for a global footprint via direct (enterprise) sales once the platform launches, and the company has built basic digital infrastructure — a website with cookie-based analytics and a privacy-policy-anchored email/newsletter channel — to support pre-launch demand generation.

Protogenix's business model has not yet been articulated in commercial terms. The company is currently pre-revenue, with no disclosed pricing, no named customers, and no segment-level revenue mechanics. Its operating activity consists of product development and capital formation: approximately $1.97 million has been raised across four rounds between April 2023 and February 2026, including a seed round led by SOSV (formerly IndieBio) in 2023, and an SEC Form D filed in February 2026 seeking up to an additional $4.2 million under Rules 506(b) and 506(c). Use of proceeds is allocated to working capital and product development, with roughly $364,000 earmarked for payments to executive officers, directors, or promoters.

Name

Protogenix, Inc

Legal name

Protogenix Inc.

Website

https://proto-genix.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Protogenix, Inc. is a pre-revenue biotechnology company developing a proprietary recombinant protein production platform intended to replace mammalian-based systems, headquartered in Ithaca, New York, with first product launch pending.

Ownership category

akta.pro rank

Product category

Biotechnology — Recombinant Protein Production

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

akta.pro secondary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Recombinant protein production
• Biotechnology platform
• Protein expression systems
• Biopharmaceutical manufacturing
• Life sciences technology

Headquarters

HQ city

Ithaca

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Biotechnology Products: Protogenix is a biotechnology company developing recombinant protein products. As a pre-revenue company currently raising seed capital, the expected revenue model would involve commercializing biotechnology products, though specific revenue mechanics are not yet disclosed.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Protogenix is developing a novel platform for recombinant protein production intended to replace the conventional mammalian protein expression system. The company is in pre-commercialization stage, with its product offering not yet launched (website displays a 'Coming Soon' page) and is currently raising seed capital for product development and working capital.

Product overview

Protogenix, Inc is a Delaware-incorporated biotechnology company founded in 2021 and based in Ithaca, New York, focused on recombinant protein production. The company's website currently displays a 'Coming Soon' message, indicating the product is in development stage. No specific named products, modules, or distinct offerings have been publicly launched or detailed in the available source material.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• ORF Genetics: ORF Genetics uses barley-grain-based expression for recombinant proteins, including growth factors and cytokines. It is a direct non-mammalian production competitor in the recombinant protein space.
• Dyadic International: Dyadic develops the C1 fungal expression platform to produce recombinant proteins as a non-mammalian alternative. It is the most direct functional comparable to Protogenix's stated mission of replacing mammalian protein production systems.
• Protalix BioTherapeutics: Protalix uses its ProCellEx plant-cell-based platform to manufacture recombinant therapeutic proteins (e.g., Elelyso for Gaucher disease), directly addressing the same displacement-of-mammalian opportunity Protogenix targets.
• Leaf Expression Systems: Leaf Expression Systems uses plant-based transient expression to produce recombinant proteins and vaccines. It is a direct alternative-chassis peer competing for the same customer set of biologic developers seeking non-mammarian systems.
• Eleva Biologistics: Eleva produces recombinant therapeutic proteins in moss-based systems (Bryotechnology). It is a niche alternative-chassis player pursuing the same biologics-manufacturing displacement thesis as Protogenix.

Broad incumbents

• Ginkgo Bioworks: Ginkgo Bioworks is a large, publicly traded synthetic biology platform that engineers organisms (including for protein production). It is a broader incumbent with adjacent capabilities rather than a direct alternative-chassis competitor for therapeutic proteins.
• Lonza Group: Lonza is the world's largest biologics CDMO and the dominant mammalian (CHO) cell culture manufacturer. It represents the incumbent infrastructure Protogenix would need to displace and a potential future customer or competitor.
• Catalent: Catalent is a major global biologics CDMO with significant mammalian-cell manufacturing capacity. It is a representative incumbent in the protein production landscape that any alternative-chassis platform must compete against or partner with.

Emerging players

• Codexis: Codexis engineers enzymes and proteins via directed evolution and has expanded into therapeutic protein engineering. It is a partial-overlap emerging player that competes on protein engineering platforms relevant to Protogenix's protein production mission.
• Amyris: Amyris used synthetic biology and engineered yeast strains to produce high-value molecules at scale, demonstrating both the promise and the execution difficulty of alternative-chassis biology businesses — a relevant precedent for Protogenix's path.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Protogenix, Inc